Pei-Yan Kong
Overview
Explore the profile of Pei-Yan Kong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan X, Wang X, Zhang C, Zhao X, Yao H, Chen G, et al.
Curr Med Sci
. 2023 Jun;
43(4):733-740.
PMID: 37330456
Objective: This study aimed to compare the efficacy of anti-CD19 chimeric antigen receptor T cells (CAR-T cells) versus chemotherapy plus donor lymphocyte infusion (chemo-DLI) for treating relapsed CD19-positive B-cell acute...
2.
Ma Y, Wei Z, Xu Y, Shi J, Yi H, Lai Y, et al.
Cancer
. 2023 Mar;
129(13):2013-2022.
PMID: 36951498
Background: Minimal residual disease (MRD) is an important prognostic factor for survival in adults with acute leukemia. The role of pretransplantation MRD status in myelodysplastic syndrome with excess blasts (MDS-EB)...
3.
Chong S, Zhao P, Huang R, Zhou H, Zhang J, Hou M, et al.
Blood Adv
. 2022 Jun;
6(14):4320-4329.
PMID: 35679462
Intracranial hemorrhage (ICH) is a rare and life-threatening hemorrhagic event in patients with immune thrombocytopenia (ITP). However, its mortality and related risk factors remain unclear. Herein, we conducted a nationwide...
4.
Wen Q, Gao L, Xiong J, Li Q, Wang S, Wang J, et al.
Curr Med Sci
. 2021 Jul;
41(3):465-473.
PMID: 34218355
The role of autologous hematopoietic stem cell transplantation (auto-HSCT) following high-dose chemotherapy has been validated and accepted as a standard treatment for patients with relapsed diffuse large B-cell lymphoma (DLBCL)....
5.
Zhang C, Wang X, Zhang R, Liu F, Wang Y, Yan Z, et al.
Leukemia
. 2020 Oct;
35(6):1563-1570.
PMID: 33077866
Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells) in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after an allotransplant remain unclear. Forty-three subjects...
6.
Zhao P, Hou M, Liu Y, Liu H, Huang R, Yao H, et al.
Platelets
. 2020 Jul;
32(5):633-641.
PMID: 32614630
Intracranial hemorrhage (ICH) is a devastating complication of immune thrombocytopenia (ITP). However, information on ICH in ITP patients under the age of 60 years is limited, and no predictive tools...
7.
Zhang C, Tan X, Yao H, Liu Y, Gao L, Gao L, et al.
Transplant Proc
. 2019 Nov;
51(9):3159-3162.
PMID: 31711585
Background: Allogenic hematopoietic stem cell transplantation may be the best currently available method to treat relapsed hemophagocytic lymphohistiocytosis (HLH) related to Epstein-Barr virus. The high rate of transplantation-related complications was...
8.
Zhang C, Ma Y, Liu J, Liu Y, Gao L, Gao L, et al.
Medicine (Baltimore)
. 2019 Jul;
98(29):e16498.
PMID: 31335716
Rationale: Relapse is the main cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Unfortunately, there are no efficient methods to prevent relapse after allo-HSCT. Chimeric antigen receptor T...
9.
Zhang C, Kong P, Li S, Chen T, Ni X, Li Y, et al.
J Immunother
. 2018 Jun;
41(6):306-311.
PMID: 29864079
Background: Reduced-intensity conditioning (RIC) regimens with low tolerable toxicities have been used for allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the relapse rate by this treatment is high. Treatment of...
10.
Shen Z, Zeng D, Wang X, Ma Y, Zhang X, Kong P
Oncol Lett
. 2016 Dec;
12(5):3278-3284.
PMID: 27899994
The bone marrow microenvironment provides a relative sanctuary from cytotoxic drugs for leukemia cells. The present niche models concentrate on a two-dimensional (2D) co-culture system , which does not imitate...